How Is Zoetis’ Stock Performance Compared to Other Pet Care Stocks?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ZTS?
Source: NASDAQ.COM
Company Overview and Stock Performance: Zoetis Inc., a leading producer of animal health products, has seen its stock decline 16.5% from its 52-week high, with a notable drop of 8.9% over the past year despite better-than-expected financial results for Q4 and fiscal 2024.
Future Outlook and Analyst Sentiment: Although Zoetis expects stagnant revenue growth for fiscal 2025, analysts maintain a "Strong Buy" rating on the stock, with a price target suggesting a potential 25.4% increase from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.930
Low
130.00
Averages
154.20
High
200.00
Current: 115.930
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stablecoins Evolving into Macro-Relevant Financial Layer
- Market Size Growth: The total supply of stablecoins has surpassed $300 billion, a significant increase from approximately $30 billion in 2020, indicating their rising importance in the global financial system and potential to reshape payments, remittances, and asset tokenization.
- Link to U.S. Treasuries: Stablecoin issuers typically invest in low-risk liquid assets like U.S. Treasury bills, making them important marginal buyers of short-dated government debt, thereby establishing a new connection between global payment demand and U.S. Treasury markets.
- Geographic Expansion Trend: The adoption of stablecoins is expanding in emerging economies facing inflation, currency depreciation, or capital controls, where digital dollar tokens serve as a store of value and provide access to dollar-based financial services outside the traditional banking system.
- Competitive Pressure on Banks: The growth of stablecoins may draw funds away from traditional bank deposits, particularly non-interest-bearing transaction accounts, forcing banks to compete more aggressively for funding, which could impact their operational models and profitability.
See More
Zoetis CEO to Participate in Healthcare Forum
- Executive Participation: Zoetis CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, at 10:30 AM ET, showcasing the company's leadership in animal health.
- Live Webcast Available: The audio webcast of the event will be accessible via the Zoetis investor website, ensuring that global stakeholders can stay updated on the company's latest developments, enhancing transparency.
- Company Background: As the world's leading animal health company with nearly 75 years of history, Zoetis is dedicated to advancing the future of animal care through innovation, serving veterinarians, livestock producers, and pet owners in over 100 countries.
- Innovation-Driven Growth: The company leverages deep scientific expertise and data-driven R&D to continuously deliver medicines, vaccines, and digital solutions, aiming to elevate animal health standards and meet customer needs.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
Zoetis CFO to Participate in Investor Conferences
- Investor Conference Schedule: Zoetis CFO Wetteny Joseph will participate in the Leerink Global Healthcare Conference on March 9, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, showcasing the company's leadership in animal health.
- Live Webcast Access: Interested investors can access live audio webcasts of the presentations via the Zoetis investor website, ensuring transparency and enhancing engagement with stakeholders.
- Company Background: With nearly 75 years of history, Zoetis is dedicated to advancing animal health, supporting veterinarians, livestock producers, and pet owners in over 100 countries, demonstrating its significant industry impact.
- Future Development Vision: Zoetis aims to set new standards for animal care through scientific R&D, advanced manufacturing, and commercial excellence, reflecting its customer obsession and purpose-driven corporate culture.
See More
Zoetis Stock Falls 1.4% Following $160 Million Acquisition of Neogen's Animal Genomics Division
- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
See More
Stablecoins Evolving into Macro-Relevant Financial Layer
- Market Size Growth: The total supply of stablecoins has surpassed $300 billion, a significant increase from approximately $30 billion in 2020, indicating their rising importance in the global financial system and potential to reshape payments, remittances, and asset tokenization.
- Link to U.S. Treasuries: Stablecoin issuers typically invest in low-risk liquid assets like U.S. Treasury bills, making them important marginal buyers of short-dated government debt, thereby establishing a new connection between global payment demand and U.S. Treasury markets.
- Geographic Expansion Trend: The adoption of stablecoins is expanding in emerging economies facing inflation, currency depreciation, or capital controls, where digital dollar tokens serve as a store of value and provide access to dollar-based financial services outside the traditional banking system.
- Competitive Pressure on Banks: The growth of stablecoins may draw funds away from traditional bank deposits, particularly non-interest-bearing transaction accounts, forcing banks to compete more aggressively for funding, which could impact their operational models and profitability.
See More
Zoetis CEO to Participate in Healthcare Forum
- Executive Participation: Zoetis CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, at 10:30 AM ET, showcasing the company's leadership in animal health.
- Live Webcast Available: The audio webcast of the event will be accessible via the Zoetis investor website, ensuring that global stakeholders can stay updated on the company's latest developments, enhancing transparency.
- Company Background: As the world's leading animal health company with nearly 75 years of history, Zoetis is dedicated to advancing the future of animal care through innovation, serving veterinarians, livestock producers, and pet owners in over 100 countries.
- Innovation-Driven Growth: The company leverages deep scientific expertise and data-driven R&D to continuously deliver medicines, vaccines, and digital solutions, aiming to elevate animal health standards and meet customer needs.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
Zoetis CFO to Participate in Investor Conferences
- Investor Conference Schedule: Zoetis CFO Wetteny Joseph will participate in the Leerink Global Healthcare Conference on March 9, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, showcasing the company's leadership in animal health.
- Live Webcast Access: Interested investors can access live audio webcasts of the presentations via the Zoetis investor website, ensuring transparency and enhancing engagement with stakeholders.
- Company Background: With nearly 75 years of history, Zoetis is dedicated to advancing animal health, supporting veterinarians, livestock producers, and pet owners in over 100 countries, demonstrating its significant industry impact.
- Future Development Vision: Zoetis aims to set new standards for animal care through scientific R&D, advanced manufacturing, and commercial excellence, reflecting its customer obsession and purpose-driven corporate culture.
See More
Zoetis Stock Falls 1.4% Following $160 Million Acquisition of Neogen's Animal Genomics Division
- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
See More
